title: Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity.
abstract: The effects of treatment of patients with gonadotrophin-releasing hormone analogue (GnRHa) combined with purified follicle stimulating hormone (FSH) for in-vitro fertilization (IVF) were investigated in detail to determine the influences of different administration routes and the degree of suppression of luteinizing hormone (LH). Responses to exogenous gonadotrophins were studied in infertile women (n = 60) with normal menstrual rhythm whose endogenous gonadotrophin activity was suppressed using a GnRHa in a long protocol. They were randomized to receive i.m. administration of human menopausal gonadotrophins (HMGim, Pergonal) or purified follicle stimulating hormone (FSH, Metrodin High Purity) administered either i.m. (MHPim) or s.c. (MHPsc). Responses were assessed by measuring plasma FSH, LH, oestradiol, testosterone and progesterone. After stimulation day 4, the MHPsc group showed significantly higher circulating concentrations of FSH than either the MHPim or HMGim group. However, the HMG group showed significantly higher oestradiol concentrations after stimulation day 5 than either MHP group. The differences in circulating oestradiol concentrations in the MHP-treated patients appeared to be strongly influenced by the mean circulating concentrations of LH in the follicular phase. The patients who showed mean follicular phase LH concentrations of < 1 IU/l showed longer follicular phases, lower circulating oestradiol and testosterone concentrations and also lower follicular fluid concentrations of oestradiol and testosterone, indicating a reduction in the normal follicular metabolism of progesterone to androgens and oestrogens under these conditions. This group of patients also showed longer follicular phases, which may have consequences for future clinical management.
authors.affiliation: Univesity Department of Obstetrics and Gynaecology, Royal Infirmary, Glasgow, UK.
authors.forename: R
authors.initials: R
authors.lastname: Fleming
authors.forename: C C
authors.initials: CC
authors.lastname: Chung
authors.forename: R W
authors.initials: RW
authors.lastname: Yates
authors.forename: J R
authors.initials: JR
authors.lastname: Coutts
mesh_terms: D000328:Adult; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000494:pharmacology / Q000652:urine; D005498:Follicular Phase / Q000097:blood; D006728:Hormones / Q000097:blood*; D006801:Humans; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood*; D008596:Menotropins / Q000008:administration & dosage / Q000494:pharmacology*; D009994:Osmolar Concentration; D013997:Time Factors
chemical_list: D006728:Hormones; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone